Summary & Overview
HCPCS Level II J8611: Methotrexate (jylamvo), Oral, 2.5 mg
HCPCS Level II code J8611 designates oral methotrexate (jylamvo) in the 2.5 mg tablet strength. This code identifies a commonly prescribed disease-modifying antirheumatic drug and oncology-adjunct medication available in outpatient pharmacy and clinic settings. Nationally, standardized HCPCS coding for oral methotrexate supports consistent billing, pharmacy reimbursement, and utilization monitoring across public and private payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, where the service is typically provided, and what billing teams should expect when this product is dispensed or billed. The publication covers benchmark pricing and coverage considerations, common billing modifiers, and the clinical indications that typically drive use of oral methotrexate formulations. It also highlights administrative and policy updates relevant to HCPCS-level drug coding and outpatient pharmacy claims processing.
This summary is intended for billing managers, pharmacy directors, and revenue cycle professionals seeking a national perspective on coding, coverage, and operational implications of HCPCS Level II code J8611. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J8611 represents Methotrexate (jylamvo), oral, 2.5 mg. The code is used to bill for oral methotrexate tablets in the 2.5 mg strength.
Service Type: Oral medication administration / Pharmacy-dispensed outpatient medication.
Typical Site of Service: Outpatient pharmacy, retail pharmacy, clinic-administered oral therapy.
Clinical & Coding Specifications
Clinical Context
A 54-year-old female with rheumatoid arthritis is prescribed oral methotrexate as disease-modifying antirheumatic therapy. She receives J8611 billed for Methotrexate (jylamvo), oral, 2.5 mg dispensed by a specialty pharmacy and refilled monthly. Typical workflow: rheumatology documents diagnosis, medication tolerance and dose, obtains baseline labs (CBC, CMP, hepatic panel) and documents informed discussion about teratogenicity and contraception. Primary care or rheumatology places the prescription and coordinates laboratory monitoring every 4–12 weeks depending on dose and clinical stability. Pharmacy dispenses tablets with NDC-level labeling; claim for J8611 is submitted to the patient’s medical benefit or pharmacy benefit per payer rules. Typical site of service is an outpatient clinic or outpatient pharmacy; medication administration is oral self-administered at home. The clinical scenario may require prior authorization, step therapy documentation, and coordination with infusion/specialty pharmacy for benefits verification and patient education.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default | Use when no special circumstances apply to the claim for . |